Pozen's aspirin-omeprazole combos set for progress on new data, clearer timelines
This article was originally published in Scrip
With a clear path forward outlined by the US FDA for its drug candidates intended to reduce gastrointestinal side effects of aspirin therapy, Pozen presented two sets of Phase III data at the American Heart Association (AHA) Scientific Sessions in Los Angeles that showed a lower occurrence of gastric ulcers with PA32540 versus a 325mg dose of enteric-coated aspirin.
You may also be interested in...
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.